News & Comments

The Biotech Rally, the New FDA Commissioner and the Companies that Would Benefit

We examined many explanations about the rallying in the biotech stocks, including the reports stating that the President’s threatening of a crackdown on pricing may have been misinterpreted. A more …

Can the Changes Rejuvenate Regulus’ Stock? Alport Syndrome Investigational Drug Advances in Trials

Since Regulus (RGLS) lead candidate drug RG101 for HCV was put on clinical hold by the FDA in 2016, the stock has enormously suffered and with it the firm’s value. Finally, we are experiencing a …

Juno Also has Great News from Its CAR-T Cell Approach

Juno’s (JUNO) JCAR017 and JCAR014 are chimeric antigen receptor T cell (CAR-T) product candidates that target CD19, a protein expressed on the surface of almost all B cell malignancies. These …

 

Today’s Highlights

Congratulations: The FDA Approved Portola’s Anticoagulant Drug Bevyxxa (betrixaban). The Stock Rallied.

Portola (PTLA) announced that the U.S. Food and Drug Administration (FDA) has approved Bevyxxa (betrixaban), the first anticoagulant for hospital and …

Data From ASCO and Data from the Internet

As we wrote in the Prohost Letter #409, a transformation in this year’s American Society of Clinical Oncology meeting (ASCO) is further …

FDA Breakthrough Therapy Designation for Alnylam’s RNAi Drug Givosiran

nylam Pharmaceutical (ALNY) calls RNAi (RNA interference) a revolution in biology. The FDA’s just granted the firm’s RNAi therapy breakthrough …

CAR-T Great News and About the Biotech Sector in General

It is obvious that the CAR-T approach to cancer treatment is here to stay and to change the way cancer has been managed for decades. Attempts to …

Our Most Commented Articles:

Congratulations: The FDA Approved Portola’s Anticoagulant Drug Bevyxxa (betrixaban). The Stock Rallied.

Portola (PTLA) announced that the U.S. Food and Drug Administration (FDA) has approved Bevyxxa (betrixaban), the first anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous …

The Biotech Rally, the New FDA Commissioner and the Companies that Would Benefit

We examined many explanations about the rallying in the biotech stocks, including the reports stating that the President’s threatening of a crackdown on pricing may have been misinterpreted. A more convincing …

Top